215 results on '"Moy, B."'
Search Results
2. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
3. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
4. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial
5. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
6. Measuring decision quality: Psychometric evaluation of a new instrument for breast cancer chemotherapy
7. Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011
8. CO168 Adaptive Behaviors Over Time in Children and Young Adults With Classic Galactosemia
9. A Phase I Study of Adjuvant Niraparib Administered Concurrently with Postoperative Radiation Therapy in Patients with Localized Triple Negative Breast Cancer
10. Leptomeningeal Disease in Breast Cancer: Pre-Treatment Prognostic Factors and Outcomes
11. 161P Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
12. 45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial
13. Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
14. Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+HR+ breast cancer after trastuzumab-based therapy on patient outcomes
15. 358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
16. 83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes
17. 1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial
18. Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
19. Local���regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
20. PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial
21. Population effectiveness model of the consequences of recurrences following treatment with trastuzumab among women with HER2+ early stage breast cancer in the United States
22. Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial
23. Abstract GS2-03: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients
24. Abstract PD9-06: Paired pre- and post-treatment DNA sequencing identifies genomic alterations mediating clinical resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
25. Abstract P4-01-06: Comparison of tumor genotyping and cell-free circulating tumor DNA sequencing in metastatic breast cancer patients and their utility in the selection of matched therapy
26. Abstract P4-08-08: Genomic progression, detected by circulating tumor DNA (ctDNA) sequencing, as an early predictor of disease progression in metastatic breast cancer (MBC)
27. Abstract P1-17-02: Outcomes and safety of paclitaxel and granulocyte-colony stimulating factor (GCSF) in breast cancer in pregnancy (BCP) - A multi-institutional retrospective analysis
28. Abstract P2-14-19: Surgical and long-term outcomes of patients receiving neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer
29. Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial
30. P005 - Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
31. Neratinib after trastuzumab (T)-based adjuvant therapy in early- stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial
32. Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial
33. Abstract PD1-13: Somatic BRCA mutation detection by circulating tumor DNA analysis in patients with metastatic breast cancer: Incidence and association with tumor genotyping results, germline BRCA mutation status, and clinical outcomes
34. Abstract P5-20-02: HER2 mutations detected by ctDNA in ER+/HER2- metastatic breast cancer patients: Incidence and impact on clinical outcomes
35. Abstract P2-02-18: Higher mutation burden and mutant allele fraction of circulating tumor DNA corresponds to worse progression free survival in metastatic breast cancer patients
36. Abstract PD3-01: Immune profile of small HER2+ tumors in the APT trial
37. Abstract P1-13-05: Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial
38. Abstract PD3-12: PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial
39. Abstract P3-10-14: Clinical and economic burden of HER2-positive breast cancer recurrence in the US: A literature review
40. Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial
41. Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial
42. 318P - Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
43. Abstract P5-16-16: Role of tumor microenvironment, as assessed by breast MRI background parenchymal enhancement (BPE), in modulating response to neoadjuvant chemotherapy in young women with localized breast cancer
44. Abstract P1-05-05: Comparison of genotyping results from tissue and circulating DNA (ctDNA) in patients with metastatic breast cancer
45. Abstract P1-06-03: Serial evolution of hormone receptor status and mutational profile among patients with metastatic breast cancer
46. Abstract P5-13-09: Development and implementation of a patient-centered, nurse practitioner-led survivorship intervention for breast cancer
47. Abstract P1-12-03: Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer
48. Association Between the 21-Gene Recurrence Score and Isolated Local-Regional Recurrence in Hormone Receptor-Positive Breast Cancer
49. P012 - Population effectiveness model of the consequences of recurrences following treatment with trastuzumab among women with HER2+ early stage breast cancer in the United States
50. P011 - Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.